Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
The way i see it...
Great RNS - encouraged lots of buying; a lot of which would have been >5p and even higher
They may have been a fair bit of selling too - but most LTHers will still be retaining majority of their shares
So - in my ind it is almost inevitable we'll see 6-7-8p very soon - if not today, then next week.
No chance of Placing today as the compnay has already exhausted its annual quote for shares.
Prevail took a 1% investent in Hemo at 6p prior to FDA approval. The consensus aongst most long term holders is that the funding will come via Prevail - probably as lead investor and may not come at a discount.
Valuation has been discussed on here for years!
The general consensus is that a market cap of c£100m is very realistic and appropriate for a Biotech making this signifcant breakthrough.
Its still only one more step on the ladder; Good results for CAR-T in Phase 1 will send this very high indeed and Hemo has a 2nd clcincial candidate in CBR which has the genuine potential to surpass anything we could imagine. Its being tested in US Gov controlled labs on live versions of the worlds deadliest viruses and has also shown proof on concept on cancer tumours
Hats off to Vlad and the team
And lets not forget the biggest and most exciting reason we are all here
C B R :-)
Thanks to a few de-rampers for your comedy attempts to downplay....
As hard as the clincial hold was to receive 7 months ago - it has GONE now :-)
HEMO CAR-T is safer as a result and HEMO will have learnt more and refined a number of aspects in that time
Prevail are lines up to kick off trials with 'realtime ' results available to Hemogenyx.
This als started with some very clever mice that have as close to a human immune system as any other mice that came before them - that gives me extra confidence and optimism going into trials
Raise a glass to Vlad and his Mighty Mice
Apologies to JD Sports s/holders. Just responding to LongerGuy. Its not a cross ramp
I've been in HEMO for 4 years and the RNS that Ive been waiting for for 4 years landed today. They are now officially a Clincial Biotech. The SP has done well in the last 4 weeks, so some of the rise has been in anticipation but myself and other LTHers believe an mcap of up to £100m is reasonable now which is more than double the current SP
The 2 others that I have shoed genuine conviction to are:
MMAG - currently priced to fail, but I am confident it is still a good business. It released encouraging H2 results before xmas and a successful entrpreneur bought 1% at 11p a share at the start of January. I believe 30-50p is the right value and the company is in an 'offer period' seeking a buyer
XPF - This company ownes two big up and coming leisure brands. Escape Hunt (Escape Rooms) and Boom Battle Bars. Share price has yet to react to a number of very strong trading updates. It has doubled revenue 2 years on the trot and is still growing. I'm targeting 30-40p
All HIGH risk - but with HIGH risk comes the possibility of HIGH reward
This is the news we were all waiting for - there was absolutley no guarantee that today was come. As Long Term shareholders in Hemo we have experienced 2-3 False dawns and a few dark days.
This affirms Hemogenyx science - teh FDA are bascially satisfied that Hemo CAR-T is safe to test on Humans.
So many drugs and therapies never make it to this signifcant milestone AND many Biotechs fail to make it here too. Those that do have usually spent a LOT more than Hemogenyx.
I'm 100% confident that this underpins a market value of c£100m (which would be a share price of c.9pence
However, share prices do not go up in a straightline (very often) so we should expect volatility and some MM tactics to maintain a market.
Goatilicious
So much to learn in this game; be VERY careful investing any significant sums of money until you've done a good year or so of investing small amounts.
Shorting is not as bad as it sounds - but can be damaging to some compnaies, particularly smaller ones. The shorters dont hang around for ever and the shares usually get a good bounce when the shorters have to buy back the shares to return to lender - see what i did there :-)
If the game was easy - everyone would make money
Best to invest with a 3-5 year minimum horizon
Dont invest in too many different shares as you won't have time to stay well researched
Often the best time to buy is when others are fearful - I would happily buy JD Sports right now - with a 3-5 year horizon
I'm currently playing a riskier game and in 3 of 4 shares I think are materially undervalued and expect them to re-rate within weeks/months. But never any guarantees and easy to get big calls wrong
Let's hope the market understand the significane of this short but sweet, beautifully formed RNS
3-4 years in the making - £10m+ invested + Blood, Sweat and Tears
A long way to go - but a huge step and a great day for patients, employees and shareholders
GLA
I'll have a go for starters
1. The lender of the shares gets a fee for lending them
2. The person who has borrowed them, will sell them st8 away and then buy them back at a later date to return to who they borrowed them from
3. I assume that the benefit to the party who is lending is (1) The size of the fee and (2) they take a long term view on the shares and are not concerned if the share price dips temporarily
Nice looking late reported trade at a premium.
I expect this to start moving now
Wowsers - MMS quoting 3.9p for over 1/2 millions
Very nice indeed - they want our shares!
Nice to see a bit of upward momentum - perhaps the shackles are off.
Someone picked up a shed load at 14.75p
Hi Moniman - my MMAG buddy
I took a small position at 21p - it almost looks to good to be true
I did note that not only have Jazz agreed the commercials for global rights to the KRAS Inhibitor Program - they have also agreed to pay RedX to perform research and preclinical development activities with the goal of completing IND-enabling studies for both KRAS profiles - so this will help fund the team
I genuinely expect Hemo to get news today or tomorrw (US time)
So big chance of intra day RNS in my view - I don't think they would want to hold off until Monday
Vlad wont be able to keep it secret through the weekend!
Absolutely - I do not value the current business at £200m
Howvere - I do not value the business at £10 either
The truth as ever is somewhere in between
Re: Kiosks
You can trust the view of dhton who has consistenlt drops in to be critical
or
You can believe what was shared by the CEO and CFO of MusciMagpie in H2 last year where they confirmed that they source >40% of their UK Consumer Tech through the Kiosks. I would love to se ethem do a good deal with Asda to encourage custoemrs to use them; think , 20% off your bill today when you trade in an old phone
400k volume today with what looks to be at least 300k of them buys
Some late in the day action fro someone
Anyone else track thenumbers - would be good to get other's views.
NewBoy - this is profitable...
Im of the opinion that the SP is being held to fill an ordre - have you not seen up to 1m bought at 14.75 in the last few weeks when everyone else has to pay 15p+
Here's my view of the 2023 Numbers (Based on my own research and workings)
Revenue: £45m +94% YOY (vs £22.8m in FY22)
Gross Margin: c£29m +94% YOY (vs £14.8m in FY22)
Site Level EBITDA: c£18m +130% YOY (vs £7.7m in FY22)
Adj EBITDA: c£9.6m +150% YOY (vs £3.9m in FY22)
Adj EBITDA Margin %: c22% (vs 17% in FY22)
Cash Generative
Each Owner Operated EH Venue - £0.55m Revenue / £0.27m Adj EBITDA
Each Owner Operated Boom Venue - £1.45m Revenue / £0.41m Adj EBITDA
I do expect them to show a Net profit; However, the key numbers are the Gross MArgin and Adj EBITDA margin. Private Equity will be looking at these (and the growth opportunity) licking their lips